PACIFIC Trial Leads to Durvalumab Approval in United States
The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are...
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO
Posted: February 2018
The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For...
Immunotherapy Adverse-Event Treatment Resource Guide
The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...
Management of Immunotherapy Toxicity in NSCLC
By Beth Eaby-Sandy, MSN, CRNP
Posted: February 2018
When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was...
Exploring the Potential of Immuno-oncology Combination Therapy
By Cynthia L. Kryder, MS, CCC-Sp
Posted: October 2017
Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy,...
The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside
Posted: June 2017
By Cynthia L. Kryder, MS
Decades of immunology research have shown that it is possible to harness the power of the immune system...
PD-L1 Blueprint Project
Posted: February 2017
By Fred R. Hirsch, MD, PhD
In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In...
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC...
Posted: February 2017
By Melody Watson
The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in...
Changing Landscape of Front-line Immunotherapy
By Naiyer A. Rizvi
The rapid development of anti-PD-1 and PD-L1 antibodies in cancer underscores the tremendous impact they have had on the cancer landscape...
PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016
By Erik J. MacLaren, PhD
Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...
